Does Dabrafenib Plus Trametinib Offer Survival Benefit in Metastatic Melanoma?
September 3rd 2019A pooled analysis included extended-survival data from COMBI-d and COMBI-v trials, both of which included treatment-naïve patients with unresectable or metastatic melanoma who were randomized to receive either dabrafenib plus trametinib or BRAF inhibitor monotherapy.
Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in Remission
June 20th 2019Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.